711 related articles for article (PubMed ID: 19273538)
21. Methotrexate for psoriasis: current European practice. A postal survey.
Boffa MJ
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):196-202. PubMed ID: 15752290
[TBL] [Abstract][Full Text] [Related]
22. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
Laharie D; Seneschal J; Schaeverbeke T; Doutre MS; Longy-Boursier M; Pellegrin JL; Chabrun E; Villars S; Zerbib F; de Lédinghen V
J Hepatol; 2010 Dec; 53(6):1035-40. PubMed ID: 20801541
[TBL] [Abstract][Full Text] [Related]
23. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.
Rosenberg P; Urwitz H; Johannesson A; Ros AM; Lindholm J; Kinnman N; Hultcrantz R
J Hepatol; 2007 Jun; 46(6):1111-8. PubMed ID: 17399848
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate in psoriatic arthritis.
Singh YN; Verma KK; Kumar A; Malaviya AN
J Assoc Physicians India; 1994 Nov; 42(11):860-2. PubMed ID: 7868484
[TBL] [Abstract][Full Text] [Related]
25. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
[TBL] [Abstract][Full Text] [Related]
26. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
27. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists.
Collin B; Srinathan SK; Finch TM
Br J Dermatol; 2008 Apr; 158(4):793-800. PubMed ID: 18241256
[TBL] [Abstract][Full Text] [Related]
30. Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis.
Keim D; Ragsdale C; Heidelberger K; Sullivan D
J Rheumatol; 1990 Jun; 17(6):846-8. PubMed ID: 2388211
[TBL] [Abstract][Full Text] [Related]
31. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
Busger Op Vollenbroek FTM; Doggen CJM; Janssens RWA; Bernelot Moens HJ
PLoS One; 2018; 13(3):e0194401. PubMed ID: 29570708
[TBL] [Abstract][Full Text] [Related]
32. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.
Lieber CS; Weiss DG; Paronetto F;
Alcohol Clin Exp Res; 2008 Jun; 32(6):1031-9. PubMed ID: 18422837
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate hepatotoxicity and concentrations of methotrexate and folate in erythrocytes--relation to liver fibrosis and cirrhosis.
Zachariae H; Schrøder H; Foged E; Søgaard H
Acta Derm Venereol; 1987; 67(4):336-40. PubMed ID: 2445154
[TBL] [Abstract][Full Text] [Related]
34. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
Langman G; Hall PM; Todd G
J Gastroenterol Hepatol; 2001 Dec; 16(12):1395-401. PubMed ID: 11851839
[TBL] [Abstract][Full Text] [Related]
35. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate.
Mitchell D; Smith A; Rowan B; Warnes TW; Haboubi NY; Lucas SB; Chalmers RJ
Br J Dermatol; 1990 Jan; 122(1):1-7. PubMed ID: 2297495
[TBL] [Abstract][Full Text] [Related]
36. [Blood cell concentration of methotrexate in long-term therapy of inflammatory rheumatic diseases].
Leeb B; Dunky A; Ogris E; Wohanka A; Schenk G; Fischer M; Tausch G; Eberl R
Acta Med Austriaca; 1988; 15(5):140-4. PubMed ID: 3146207
[TBL] [Abstract][Full Text] [Related]
37. Pancytopenia associated with low dose methotrexate therapy. A regional survey.
al-Awadhi A; Dale P; McKendry RJ
J Rheumatol; 1993 Jul; 20(7):1121-5. PubMed ID: 8371202
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients.
Barbero-Villares A; Mendoza J; Trapero-Marugan M; Gonzalez-Alvaro I; Daudén E; Gisbert JP; Moreno-Otero R
Med Clin (Barc); 2011 Nov; 137(14):637-9. PubMed ID: 21719043
[TBL] [Abstract][Full Text] [Related]
39. Systemic methotrexate therapy for psoriasis: past, present and future.
Dogra S; Mahajan R
Clin Exp Dermatol; 2013 Aug; 38(6):573-88. PubMed ID: 23837932
[TBL] [Abstract][Full Text] [Related]
40. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
